Alzamend Neuro Balance Sheet

Financials in millions USD. Fiscal year is May - April.

Millions USD. Fiscal year is May - Apr.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	5.14	14.06	1.93	0.09	0.04
Short-Term Investments	0	0	0	0.1	0.21
Cash & Cash Equivalents	5.14	14.06	1.93	0.19	0.25
Cash Growth	-63.45%	628.97%	909.03%	-23.06%	-
Other Current Assets	0.69	0.35	0.98	1.62	1.25
Total Current Assets	5.84	14.41	2.91	1.81	1.5
Property, Plant & Equipment	0.08	0.1	0	0	0
Total Long-Term Assets	0.08	0.1	0	0	0
Total Assets	5.92	14.52	2.91	1.81	1.5
Accounts Payable	2.87	1.16	0.56	0.99	1.18
Current Debt	0	0	0.34	0	0
Total Current Liabilities	2.87	1.16	0.9	0.99	1.18
Total Liabilities	2.87	1.16	0.9	0.99	1.18
Total Debt	0	0	0.34	0	0
Retained Earnings	-44.07	-29.19	-16.83	-11.79	-7.38
Shareholders' Equity	3.05	13.35	2.01	0.82	0.32
Net Cash / Debt	5.14	14.06	1.59	0.19	0.25
Net Cash / Debt Growth	-63.45%	782.32%	733.66%	-23.06%	-
Net Cash Per Share	0.79	2.37	0.33	0.04	0.06
Working Capital	2.97	13.25	2.01	0.82	0.32
Book Value Per Share	0.47	2.25	0.42	0.17	0.08

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).